Related Experiment Videos
VINCRISTINE IN THE TREATMENT OF NEOPLASTIC DISEASE.
Canadian Medical Association Journal
|June 20, 1964
Summary
Vincristine, derived from Vinca rosea, showed efficacy in advanced cancers, with notable responses in lymphomas and leukemias. However, toxic side effects like hair loss and nerve damage were common.
Area of Science:
- Oncology
- Pharmacology
- Chemotherapy
Background:
- Advanced malignant diseases present significant treatment challenges.
- Vinca alkaloids represent a class of compounds explored for their cytotoxic properties.
Purpose of the Study:
- To evaluate the efficacy and toxicity of vincristine in patients with advanced malignant disease.
- To identify specific cancer types that may respond favorably to vincristine treatment.
Main Methods:
- Seventy-eight patients with advanced cancers received vincristine treatment.
- Patient responses were evaluated based on tumor regression and resumption of activity.
- Toxic side effects were systematically recorded.
Main Results:
- Fifty-nine patients were evaluable after one month.
- Twenty patients (good response) showed >75% tumor regression and returned to activity.
- Seven patients (fair response) demonstrated ≥25% tumor regression and partial activity.
- Favorable responses observed in Hodgkin's disease, reticulum cell sarcoma, lymphosarcoma, breast carcinoma, acute leukemia, and choriocarcinoma.
- Remission duration was typically brief, but five patients exceeded six months.
- Common toxicities included alopecia, neurologic complications, and predictable bone marrow depression.
Conclusions:
- Vincristine demonstrates therapeutic activity in various advanced malignancies.
- The drug's use is associated with significant toxicities, particularly alopecia, neurological effects, and myelosuppression.
- Careful patient monitoring is essential due to the predictable side effect profile.